Wedbush Maintains Neutral on Biogen, Lowers Price Target to $268
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico maintains a Neutral rating on Biogen (NASDAQ:BIIB) and lowers the price target from $269 to $268.
July 26, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Biogen and lowers the price target from $269 to $268.
The news is directly about Biogen and its price target being lowered by Wedbush. This could potentially impact investor sentiment and the stock's price, but the change is minimal and the rating remains Neutral, indicating no major changes in the company's outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100